Pharma & Biotech News #PharmaBuzz

Market Place

Sourcing Support

Weekly News Recap #Phispers

Roche announces US$ 50 bn investment in US to avoid tariffs; Regeneron signs US$ 3 bn onshoring deal with Fujifilm

After Eli Lilly, Johnson & Johnson and Novartis, Roche has announced plans to manufacture in the US to avoid tariffs. The Swiss...

Impressions : 816

Novartis to invest US$ 23 bn in US to avoid import tariffs; Pfizer halts development of GLP-1 weight-loss pill

After Eli Lilly and Johnson & Johnson, Novartis has become the latest big pharma to announce mega investments in the US. The ...

Impressions : 842

Pharma tariffs coming soon, warns Trump; GSK, Lilly ink billion-dollar deals for blood-brain barrier technology

In this week’s news, US President Donald Trump has said “major” pharmaceutical import tariffs are coming soon...

Impressions : 1016

CBER director forced out in FDA gutting; Sanofi, Alnylam's RNAi therapy Qfitlia wins US approval for hemophilia A, B

The pharma industry saw its most tumultuous week in the recent past with the US Food and Drug Administration (FDA) facing an un...

Impressions : 927

Only few entries up to this point, click to access all

Quality Compliance Alerts #Warning!

All News #Library

Generics

Biotech

APIs

Quality

Sciences

Rare Diseases

Others

NEWS

DRUGS & DEVELOPMENTS

MARKET INTEL by PharmaCompass

Roche announces US$ 50 bn investment in US to avoid tariffs; Regeneron signs US$ 3 bn onshoring deal with Fujifilm

Novartis to invest US$ 23 bn in US to avoid import tariffs; Pfizer halts development of GLP-1 weight-loss pill

Pharma tariffs coming soon, warns Trump; GSK, Lilly ink billion-dollar deals for blood-brain barrier technology

CBER director forced out in FDA gutting; Sanofi, Alnylam's RNAi therapy Qfitlia wins US approval for hemophilia A, B

Kashiv Bio's Biologic FYLNETRA Receives Suppl Approval in US

Akeso's Biologic Penpulimab Receives Suppl Approval in US

BeiGene's Biologic Tevimbra Receives Suppl Approval in US

Centocor's Biologic Simponi Receives Suppl Approval in US

Janseen's Biologic Simponi Aria Receives Suppl Approval in US

Amgen's Biologic Bkemv Receives Suppl Approval in US

Aurobindo's Generics Esomeprazole Receives Approval in US

Micro Labs's Generics Latanoprost Receives Approval in US

Fresenius Kabi's Biologic Otulfi Receives Suppl Approval in US

BMS's Biologic Yervoy Receives Suppl Approval in US

Enforcement Report - Week of April 23, 2025

Amneal Issues a Nationwide Recall of Ropivacaine HCl

Enforcement Report - Week of April 16, 2025

PMS4PMS Receives FDA Warning Letter

Enforcement Report - Week of April 2, 2025

Health Canada Issues Recalls of Mint Pharma's Rosuvastatin

Enforcement Report - Week of March 26, 2025

Hangzhou Glamcos Biotech Receives FDA Warning Letter

Yangzhou Sion Receives FDA Warning Letter

Health Canada Issues Recalls of Sandoz's Fesoterodine

Basel Medical Acquires Bethesda Medical to Strengthen Healthcare

Merck starts $1 billion Biologics Center in Delaware, US

Pfizer Announces Another $1.7B in Cost Savings, R&D Revamp

Regeneron's first-quarter results miss on lower Eylea demand

FDA delays decision on Stealth' rare genetic disorder drug

Gilead to pay $202 M in US settlement over HIV drug kickbacks

AstraZeneca says potential US tariffs manageable

AstraZeneca's Truqap falls short in another phase 3 trial

Lilly pens $13M upfront oligonucleotide AI pact with Creyon Bio

IOL Chemicals Receives Approval CDE of NMPA, China for Ibuprofen

Navamedic ASA: Imdur® distribution agreement extended to 2032

Morepen Labs gets CDSCO clearance for Resmetirom studies

Abbott Highlights New AVEIR™ Data, Initiates Trial for Conduction

BMS Reports Mixed Earnings as Portfolio due to Generic Pressure

Novo protects US patients with legal wins against compounder

Lupin receives US FDA approval for generic Tolvaptan Tablets

Caplin Steriles approved by USFDA for Phytonadione Injectable

West Announces Q1 2025 Results, Raises EPS Guidance

Nordic Group's Subsidiary Launches Authorized Generic of Maxitrol

US generic drugs could get battered by tariffs, USP chief warns

Merck starts $1 billion Biologics Center in Delaware, US

Lilly pens $13M upfront oligonucleotide AI pact with Creyon Bio

Novartis axes osteoarthritis asset and radioligand therapy

Daiichi Sankyo reports solid launch for touted ADC Datroway

23andMe to have overseer for genetic data in bankruptcy

Protagenic Therapeutics to Effect 1-for-14 Reverse Stock Split

BrainStorm's NurOwn® Data Chosen for ISCT 2025 Presentation

WuXi Biologics Releases 2024 Sustainability Report

Genprex Collab Positive Preclinical Data on Diabetes Gene Therapy

Novavax Appoints Charles Newton to Board of Directors

May 21, 2025 General Meeting - Preparatory documents available

Morepen Laboratories expands its domestic portfolio

CARBOGEN AMCIS Shanghai Site Gets Drug Manufacturing License

Divi's Lab inks supply pact with global pharmaceutical entity

Sustainability in Pharma Manufacturing: Path to Greener Future

Pharma companies may feel heat of US tariffs on China

Pharma APIs Storage: Ensuring Quality and Compliance

Novartis unveils $23B investment to beef up US manufacturing

USP, Ginkgo Partner With ARPA-H To Boost Essential Meds

APIs At the Core of Modern Medicine

USFDA inspection at Zydus' API Unit in Dabhasa, Gujarat ends

Sun Pharma to recall Levipil 500 immediately

Zydus gets 6 observations from USFDA for API unit

Justice Department unit for drug and food safety cases disbanded

Four states request USDA to ban soda, candy from food Assistance

Ozempic copies restricted after US judge denies injunction

Lupin recalls nearly 3,000 bottles of OCD drug in US

Bausch + Lomb to Return enVista Intraocular Lenses After Recall

Delhi HC orders cough syrup makers to warn against child use

ICMR for selective ban on popular painkiller

Senseonics to link 365-day CGM to Sequel's upcoming insulin pump

Roche nets FDA breakthrough label for AI lung cancer CDx test

FDA chief: Firings won't affect drug review deadlines